Suppr超能文献

联合产前罗伊氏乳杆菌和 ω-3 补充剂协同调节新生儿辅助性 T 细胞的 DNA 甲基化。

Combined prenatal Lactobacillus reuteri and ω-3 supplementation synergistically modulates DNA methylation in neonatal T helper cells.

机构信息

Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Lab 1, Building 420, Entrance 68, Level 12, 581 83, Linköping, Sweden.

Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.

出版信息

Clin Epigenetics. 2021 Jun 30;13(1):135. doi: 10.1186/s13148-021-01115-4.

Abstract

BACKGROUND

Environmental exposures may alter DNA methylation patterns of T helper cells. As T helper cells are instrumental for allergy development, changes in methylation patterns may constitute a mechanism of action for allergy preventive interventions. While epigenetic effects of separate perinatal probiotic or ω-3 fatty acid supplementation have been studied previously, the combined treatment has not been assessed. We aimed to investigate epigenome-wide DNA methylation patterns from a sub-group of children in an on-going randomised double-blind placebo-controlled allergy prevention trial using pre- and postnatal combined Lactobacillus reuteri and ω-3 fatty acid treatment. To this end, > 866000 CpG sites (MethylationEPIC 850K array) in cord blood CD4+ T cells were examined in samples from all four study arms (double-treatment: n = 18, single treatments: probiotics n = 16, ω-3 n = 15, and double placebo: n = 14). Statistical and bioinformatic analyses identified treatment-associated differentially methylated CpGs and genes, which were used to identify putatively treatment-induced network modules. Pathway analyses inferred biological relevance, and comparisons were made to an independent allergy data set.

RESULTS

Comparing the active treatments to the double placebo group, most differentially methylated CpGs and genes were hypermethylated, possibly suggesting induction of transcriptional inhibition. The double-treated group showed the largest number of differentially methylated CpGs, of which many were unique, suggesting synergy between interventions. Clusters within the double-treated network module consisted of immune-related pathways, including T cell receptor signalling, and antigen processing and presentation, with similar pathways revealed for the single-treatment modules. CpGs derived from differential methylation and network module analyses were enriched in an independent allergy data set, particularly in the double-treatment group, proposing treatment-induced DNA methylation changes as relevant for allergy development.

CONCLUSION

Prenatal L. reuteri and/or ω-3 fatty acid treatment results in hypermethylation and affects immune- and allergy-related pathways in neonatal T helper cells, with potentially synergistic effects between the interventions and relevance for allergic disease. Further studies need to address these findings on a transcriptional level, and whether the results associate to allergy development in the children. Understanding the role of DNA methylation in regulating effects of perinatal probiotic and ω-3 interventions may provide essential knowledge in the development of efficacious allergy preventive strategies. Trial registration ClinicalTrials.gov, ClinicalTrials.gov-ID: NCT01542970. Registered 27th of February 2012-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT01542970 .

摘要

背景

环境暴露可能改变 T 辅助细胞的 DNA 甲基化模式。由于 T 辅助细胞是过敏发展的关键,因此甲基化模式的变化可能构成过敏预防干预措施的作用机制。虽然先前已经研究了单独的围产期益生菌或 ω-3 脂肪酸补充的表观遗传效应,但尚未评估联合治疗。我们旨在通过对正在进行的随机双盲安慰剂对照过敏预防试验中的一组儿童进行亚组研究,来研究产前联合使用罗伊氏乳杆菌和 ω-3 脂肪酸治疗后脐带血 CD4+T 细胞中的全基因组 DNA 甲基化模式。为此,在所有四个研究组(双重治疗:n=18,单一治疗:益生菌 n=16,ω-3 n=15,双重安慰剂:n=14)的样本中检查了超过 866000 个 CpG 位点(MethylationEPIC 850K 阵列)。统计和生物信息学分析确定了与治疗相关的差异甲基化 CpG 和基因,这些基因被用于鉴定可能由治疗引起的网络模块。途径分析推断了生物学相关性,并与独立的过敏数据集进行了比较。

结果

将活性治疗与双重安慰剂组进行比较,大多数差异甲基化的 CpG 和基因都被高甲基化,这可能表明转录抑制的诱导。双治疗组显示出最多数量的差异甲基化 CpG,其中许多是独特的,表明干预之间存在协同作用。双治疗网络模块内的簇包含免疫相关途径,包括 T 细胞受体信号转导和抗原加工和呈递,而单治疗模块中也揭示了类似的途径。来自差异甲基化和网络模块分析的 CpG 在独立的过敏数据集中富集,特别是在双重治疗组中,这表明治疗引起的 DNA 甲基化变化与过敏发展有关。

结论

产前罗伊氏乳杆菌和/或 ω-3 脂肪酸治疗导致高甲基化,并影响新生儿 T 辅助细胞中的免疫和过敏相关途径,干预之间可能具有协同作用,与过敏疾病相关。需要进一步研究来解决这些在转录水平上的发现,以及这些结果是否与儿童过敏发展有关。了解 DNA 甲基化在调节围产期益生菌和 ω-3 干预作用中的作用可能为开发有效的过敏预防策略提供重要知识。

试验注册

ClinicalTrials.gov,ClinicalTrials.gov-ID:NCT01542970。于 2012 年 2 月 27 日注册-回顾性注册,https://clinicaltrials.gov/ct2/show/NCT01542970。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/479a/8247185/77aab8280c06/13148_2021_1115_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验